BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the launch of Sensus Healthcare Financial Services, a new program intended to make it easier for dermatology practices to acquire Sensus' superficial radiotherapy (SRT) systems through a streamlined process and flexible financing structure.
Sensus Healthcare, Inc. (SRTS) Q4 2025 Earnings Call Transcript
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and twelve months ended December 31, 2025. Highlights include the following: Revenues were $4.9 million for the quarter and $27.5 million for the year Net loss was $3.2 million for the quarter and $7.7 milli.
BOCA RATON, Fla.--(BUSINESS WIRE)---- $SRTS--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the company will report fourth quarter and full year 2025 financial results on Thursday, February 12, 2026. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and ans.
Sensus Healthcare (NASDAQ: SRTS - Get Free Report) will likely be announcing its Q4 2025 results before the market opens on Wednesday, February 4th. Analysts expect the company to announce earnings of ($0.09) per share and revenue of $8.3450 million for the quarter. Individuals can find conference call details on the company's upcoming Q4 2025 earning
Envoy Medical (NASDAQ: COCH - Get Free Report) and Sensus Healthcare (NASDAQ: SRTS - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation. Risk and Volatility Envoy Medical has a
Sensus Healthcare, Inc. (NASDAQ: SRTS - Get Free Report) has earned a consensus rating of "Hold" from the five brokerages that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a buy recommendation to the company. The
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced that management will be meeting with members of the healthcare investment community January 12–14, 2026, in San Francisco during the 44th Annual J.P. Morgan Healthcare Conference. “With recently established coding by the Centers for.
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced the appointment of Larry Biscotti to its Board of Directors, effective immediately. With this appointment the Sensus Healthcare Board has six Directors, including four independent Directors. Mr. Biscotti brings more than 25 years of.
Sensus Healthcare (NASDAQ: SRTS - Get Free Report) and Venus Concept (NASDAQ: VERO - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings. Analyst Recommendations This is a summary of
